Decellularized Femoral Artery Allograft (Nexeon AVX) Prospective Registry

Recruiting

• Conditions: End-Stage Renal Disease
• Interventions: Other: Nexeon Arterial Venous Allograft

• Registration Number: NCT05880537
• Lead Sponsor: LifeNet Health

Brief Summary

Post market registry to assess the safety and efficacy of a novel decellularized human femoral artery allograft (Nexeon AVX Decellularized Femoral Artery,

Detailed Description

The clinical objective of this prospective, observational, post market registry study, CR-21-005, is to assess the safety and efficacy of a decellularized human femoral artery allograft (Nexeon AVX Decellularized Femoral Artery, LifeNet Health, Virginia Beach, VA) in the creation of vascular access for hemodialysis in patients with ESRD.

Study Timeline

• Study First Submitted: 2023-03-01
• Study First Submitted QC: 2023-05-19
• Study First Posted: 2023-05-30
• Study Start: 2023-06-06
• Status Verified: 2025-03
• Last Update Submitted: 2025-03-28
• Last Update Posted: 2025-04-02
• Primary Completion: 2027-12-15
• Study Completion: 2027-12-15

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

1. Be male or female, ≥18 years of age at the time of graft placement
2. Have a diagnosis of ESRD or renal dysfunction requiring hemodialysis
3. Subject requires dialysis access to start or maintain dialysis treatment and placement of an AV access graft is a viable access option.
4. Have the ability themselves, or through their legal guardian, to understand the requirements of the study, to provide written informed consent/assent as evidenced by signature on an informed consent form (ICF) approved by an institutional review board (IRB), and to agree to abide by the study restrictions and return to the site for the required assessments
5. Have provided written authorization for use and disclosure of protected health information

Exclusion Criteria

1. Be participating in a study of another investigational drug or device
2. Have a known sensitivity to any of the processing reagents utilized in the manufacture of this product such as antibiotics (Lincomycin, Polymyxin B, Ciprofloxacin, Meropenum, Gentamicin, or Vancomycin) and processing reagents (N-lauroyl sarcosine, Denarase and glycerol/glycerin)
3. Have a history or evidence of severe cardiac disease, myocardial infarction within 6 months, ventricular arrhythmias, or unstable angina requiring continuing treatment
4. Have a history or evidence of severe peripheral vascular disease in the upper extremities
5. Have the inability or be unable or unwilling to follow the study visit schedule
6. Have the presence of any condition that, in the opinion of the investigator, places the subject at undue risk or potentially jeopardizes the quality of the data to be generated

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Open Label	Nexeon Arterial Venous Allograft	Open Label for subjects with End-Stage Renal Disease

Primary Outcome Measures

Name	Time	Method
UltraSound evaluation of allograft functional patency.	24 months	Ultrasound proof of vessel patency and blood flow

Secondary Outcome Measures

Name	Time	Method
Secondary Endpoint:	24 months	Evaluating the emergent adverse events as it pertains to the hemodialysis access anatomical site

Trial Locations

Locations (4)

Infirmary Heath; 🇺🇸 Mobile, Alabama, United States

Olive View - UCLA Medical Center; 🇺🇸 Sylmar, California, United States

Harbor-UCLA Medical Center; 🇺🇸 Torrance, California, United States

Sentara Norfolk General Hospital; 🇺🇸 Norfolk, Virginia, United States